Suppr超能文献

剂量递增调强放疗用于局部晚期宫颈癌的治疗

Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer.

作者信息

Shewalkar Balaji, Khan Asfiya, Yerlekar Dnyanda, Patel Jitendra, Khadilkar Hrishikesh, Sakthivel Rajakumar, Kataruka Reeta

机构信息

Radiation Oncology, Government Medical College and Cancer Hospital, Aurangabad, IND.

Preventive Oncology, Government Medical College and Cancer Hospital, Aurangabad, IND.

出版信息

Cureus. 2022 Jun 15;14(6):e25965. doi: 10.7759/cureus.25965. eCollection 2022 Jun.

Abstract

Objective In this study, we aimed to assess the response and toxicity related to dose escalation in external beam radiation therapy (EBRT) using intensity-modulated radiation therapy (IMRT) with weekly concurrent cisplatin followed by de-escalated brachytherapy (BT) in locally advanced carcinoma cervix of International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIB-IIIC1. Materials and methods Fifty-two patients diagnosed with cervical cancer FIGO 2018 stage IIB-IIIC1 were treated with curative intent from November 2019 to October 2021. The dose of 50 Gy was prescribed for the primary tumor volume and elective pelvic nodal volume followed by a primary boost to a dose of 20 Gy. Gross lymph node (LN) of size >1 cm after EBRT completion received a sequential nodal boost of 10 Gy. All patients received concurrent cisplatin to a dose of 40 mg/m for a total of five to six weekly cycles. All patients received two fractions of BT to a dose of 6 Gy after EBRT completion. Radiation-induced acute toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) criteria and hematologic toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results A median follow-up of six months was available for the 40 eligible patients. All patients tolerated treatment with an acceptable toxicity profile. Grade III dermatitis, grade III gastrointestinal (GI) toxicity, and grade III genitourinary (GU) toxicity were seen in three (7.5%), six (17.5%), and three patients (7.5%) respectively. Grade I anemia was evident in all patients. At six months after EBRT completion, 37 patients (92.5%) had a complete response and only three patients (7.5%) had residual disease. Conclusion Based on our findings, patients with cervical cancer treated with dose-escalated IMRT have a satisfactory outcome with reasonably low levels of treatment-related acute GI and GU toxicities. The findings of the present study endorse the notion that the application of a high dose of external radiation to the pelvis by IMRT technique with image-guided delivery could be an acceptable alternative to the standard-dose management schedule.

摘要

目的 在本研究中,我们旨在评估在国际妇产科联盟(FIGO)2018年IIB-IIIC1期局部晚期宫颈癌患者中,采用调强放射治疗(IMRT)联合每周顺铂同步治疗,随后进行剂量递减的近距离放射治疗(BT)时,剂量递增相关的反应和毒性。材料与方法 2019年11月至2021年10月,对52例诊断为FIGO 2018年IIB-IIIC1期宫颈癌的患者进行了根治性治疗。对原发肿瘤体积和选择性盆腔淋巴结体积给予50 Gy的剂量,随后对原发灶进行20 Gy的剂量递增。在完成外照射放疗(EBRT)后,直径>1 cm的肿大淋巴结接受10 Gy的序贯淋巴结剂量递增。所有患者接受剂量为40 mg/m²的顺铂同步治疗,共五至六个周期,每周一次。所有患者在完成EBRT后接受两部分剂量为6 Gy的BT治疗。根据放射治疗肿瘤学组(RTOG)标准对放射诱导的急性毒性进行分级,根据不良事件通用术语标准(CTCAE v4.0)对血液学毒性进行分级。结果 40例符合条件的患者的中位随访时间为6个月。所有患者对治疗的耐受性良好,毒性反应可接受。分别有3例(7.5%)、6例(17.5%)和3例(7.5%)患者出现III级皮炎、III级胃肠道(GI)毒性和III级泌尿生殖系统(GU)毒性。所有患者均有I级贫血。在完成EBRT后6个月,37例(92.5%)患者完全缓解,仅3例(7.5%)患者有残留病灶。结论 根据我们的研究结果,采用剂量递增IMRT治疗的宫颈癌患者有令人满意的结局,治疗相关的急性GI和GU毒性水平合理较低。本研究结果支持这样一种观点,即通过图像引导的IMRT技术对盆腔进行高剂量外照射可能是标准剂量管理方案的一种可接受的替代方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9436/9285639/739baa3ae6cc/cureus-0014-00000025965-i01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验